Drugs News and Research

RSS

Medco Health Solutions reports third-quarter total net revenues of $14.8 billion

Medco Health Solutions, Inc. today reported record third-quarter 2009 GAAP diluted earnings per share of $0.69, up 19.0 percent compared to $0.58 for the third quarter of 2008.

3 Nov 2009

AmerisourceBergen reports increased revenues of 9%

AmerisourceBergen Corporation today reported that in its fiscal year 2009 fourth quarter ended September 30, 2009, diluted earnings per share were $0.44, a 22 percent increase, and revenue increased 9 percent to a record $18.7 billion. Earnings per share and other share-related data reflect the Company’s June 2009 two-for-one stock split.

3 Nov 2009

NIH awards $4 million research grant to AllTranz

AllTranz, Inc., a specialty pharmaceutical company focused on developing drugs to treat a variety of neurologic and inflammatory disorders, today announced that it has been awarded a $4 million research grant from the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to advance the company’s transdermal tetrahydrocannabinol (THC) patch for the treatment of marijuana dependence and withdrawal.

3 Nov 2009

Acorda Therapeutics' financial results for the third quarter of 2009 and update on Fampridine-SR

Acorda Therapeutics, Inc. today announced its financial results for the third quarter of 2009.

3 Nov 2009

Smokers with systemic lupus erythematosus at greater risk of skin damage and rashes

As if there weren't enough reasons to stop smoking, a team of researchers at the Research Institute of the McGill University Health Centre (RI-MUHC) have just found another. A study led by Dr. Christian A Pineau, Co-Director of the Lupus and Vasculitis clinic at the MUHC, has clearly linked skin damage and rashes to smoking in people with systemic lupus erythematosus (SLE). The study was published in a recent issue of the Journal of Rheumatology.

3 Nov 2009

Challenges in global health: rising to meet them could save millions of lives, say experts

Responding to the HIV/AIDS pandemic and tackling so-called neglected tropical diseases are the focus of the November/December 2009 edition of Health Affairs. The articles, by leading global health experts from around the world, show that although these challenges differ dramatically, rising to meet them could save millions of lives.

3 Nov 2009

Caliper Life Sciences presents the benefits of its LabChip GX platform

Caliper Life Sciences, Inc., a leading provider of life sciences tools, presented at a training session for reviewers from the United States Food and Drug Administration (FDA) on the benefits of the LabChip GX platform for high throughput screening and characterization assays for biological drugs.

3 Nov 2009

Seaside Therapeutics commences STX107 Phase 1 clinical trial for Fragile X Syndrome

Seaside Therapeutics LLC today announced that the Company has initiated a Phase 1 clinical trial of STX107, a highly potent, selective mGluR5 antagonist, in development for the treatment of Fragile X Syndrome. The single ascending dose study is designed to evaluate the safety, tolerability and pharmacokinetics of STX107 in healthy volunteers. Fragile X Syndrome is the most common inherited form of mental impairment and the most common known cause of autism.

3 Nov 2009

Not enough is being done to support patients suffering from tinnitus

As many as one in seven people will experience tinnitus, or ringing in their ears, at some time of their life, but not enough is being done to support patients who experience this distressing condition, according to an extensive research review in the November issue of the Journal of Clinical Nursing.

3 Nov 2009

Tyco Healthcare violates antitrust laws relating to its Nellcor pulse oximetry products

Masimo, the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low Perfusion pulse oximetry, announced today that the Ninth Circuit Court of Appeals has affirmed the 2006 Federal District Court decision that Tyco Healthcare, now Covidien, violated the antitrust laws through anticompetitive business practices related to the sale of its Nellcor pulse oximetry products.

3 Nov 2009

Tumor-penetrating microparticles may offer treatment hope for those suffering with pancreatic cancer

Tiny particles that can carry drugs and target cancer cells may offer treatment hope for those suffering with pancreatic cancer. New research to be presented in November at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting in Los Angeles reveals that tumor-penetrating microparticles (TPM) have been specifically designed to break through hard-to-infiltrate barriers and deliver drugs more effectively and efficiently than the standard form of chemotherapy such as those injected through a vein.

3 Nov 2009

Cuts in cancer care a move in the wrong direction of health care reform, says COA

The Community Oncology Alliance (COA) today criticized the newest round of cuts in cancer care as a move in the wrong direction of health care reform. Although not as devastating as expected, the cuts by the Centers for Medicare and Medicaid Services (CMS) will still decrease reimbursements far beyond what the U.S. cancer care delivery system, including most patients, can bear.

3 Nov 2009

FDA updates Byetta prescribing information following reports of kidney problems

The U.S. Food and Drug Administration today acted on new safety information about possible kidney function problems, including kidney failure, in patients taking Byetta (exenatide), a drug used to treat Type 2 diabetes.

3 Nov 2009

Senate, House split over taxes to pay for health overhaul

A health care overhaul that would expand health insurance coverage to millions isn't free, and in addition to proposed cuts, bills would raise revenue with taxes and fees. "The typical family would be spared higher taxes from the House Democratic plan to overhaul health care, and their low-income neighbors could come out ahead," the Associated Press/Boston Globe reports.

3 Nov 2009

NIH awards $2 million grant for sickle cell disease research

Researchers at the University of Illinois at Chicago will use a $2 million federal grant to investigate why patients with sickle cell disease experience chronic pain -- and to develop drugs to treat it.

2 Nov 2009

Atrial fibrillation device market will grow by almost 10% through 2013: MRG

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the atrial fibrillation device market will grow by almost 10% through 2013 in the US, Europe, and Japan. MRG's Global Markets for Atrial Fibrillation Devices 2009 report finds that many patients will be treated with electrophysiology technology and related devices as positive clinical results supporting their use emerges.

2 Nov 2009

VEGF from the retinal pigment epithelium to the choriocapillaris leads to degeneration of the CC, study finds

Scientists at Schepens Eye Research Institute have found that when the eye is missing a diffusible form of vascular endothelial growth factor (VEGF), i.e. one that when secreted can reach other cells at a distance, the retina shows defects similar to "dry" macular degeneration, also called geographic atrophy (GA).

2 Nov 2009

Avila Therapeutics presents preclinical study data of its AVL-181 HCV protease inhibitor

Avila Therapeutics™, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181. Avila showed that AVL-181 promoted complete viral clearance in vitro when used at clinically-relevant concentrations in combination with other HCV therapies.

2 Nov 2009

Pulmatrix raises $30.2 million through Series B financing

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the treatment and prevention of infectious and progressive respiratory diseases, today announced that it has secured $30.2 million in Series B financing. ARCH Venture Partners and Novartis Bioventures Fund co-led the round with participation from existing investors Polaris Venture Partners and 5AM Ventures.

2 Nov 2009

Dietary cholesterol is not a primary factor for coronary heart disease

Contrary to the established view, current data suggest that dietary cholesterol is not a primary factor of or causes heart disease - with the possible exception of the genetic forms of familial hypercholesterolemias. For instance, recent clinical trials evaluating the effect of cholesterol-lowering drugs on the development of chronic heart failure, diabetes and stroke have yielded disappointing results.

2 Nov 2009

Drugs News and Research

Medco Health Solutions reports third-quarter total net revenues of $14.8 billion

AmerisourceBergen reports increased revenues of 9%

NIH awards $4 million research grant to AllTranz

Acorda Therapeutics' financial results for the third quarter of 2009 and update on Fampridine-SR

Smokers with systemic lupus erythematosus at greater risk of skin damage and rashes

Challenges in global health: rising to meet them could save millions of lives, say experts

Caliper Life Sciences presents the benefits of its LabChip GX platform

Seaside Therapeutics commences STX107 Phase 1 clinical trial for Fragile X Syndrome

Not enough is being done to support patients suffering from tinnitus

Tyco Healthcare violates antitrust laws relating to its Nellcor pulse oximetry products

Tumor-penetrating microparticles may offer treatment hope for those suffering with pancreatic cancer

Cuts in cancer care a move in the wrong direction of health care reform, says COA

FDA updates Byetta prescribing information following reports of kidney problems

Senate, House split over taxes to pay for health overhaul

NIH awards $2 million grant for sickle cell disease research

Atrial fibrillation device market will grow by almost 10% through 2013: MRG

VEGF from the retinal pigment epithelium to the choriocapillaris leads to degeneration of the CC, study finds

Avila Therapeutics presents preclinical study data of its AVL-181 HCV protease inhibitor

Pulmatrix raises $30.2 million through Series B financing

Dietary cholesterol is not a primary factor for coronary heart disease

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News